Stay updated with breaking news from Eliot Bourk. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Chimeric Therapeutics Ltd (ASX:CHM) has signed a sponsored research agreement with the University of Pennsylvania to support the continued research and...
RaaS Advisory has valued Chimeric at a mid-case of A$243 million or A$0.74/share using a risked NPV based on its assumptions for CLTX CAR T...
“Our recent portfolio growth has resulted in the need for expertise that will allow us to rapidly advance our preclinical assets alongside...
Chimeric Therapeutics Ltd (ASX:CHM) continues to develop its oncology pipeline with novel cell therapy technologies to provide benefits to cancer patients globally. In its March quarter report, the company highlighted its healthy financial position, with $23.6 million in cash and equivalents as of March 31. Successful initial public offering During the quarter, Chimeric completed a $35 million initial public offering (IPO) and successfully listed on the ASX in January with support from new and existing institutional, professional and retail investors within Australia and overseas. Proceeds ...
Dr Bourk will lead business and corporate development, with a near-term focus on Chimeric Therapeutics’ pipeline with additional novel cell therapies.